AbbVie (ABBV) said it has received a Complete Response Letter from the FDA for the New Drug Application for ABBV-951 for the treatment of motor fluctuations in adults with advanced Parkinson's disease. The FDA cited observations that were identified during inspection of a third-party manufacturer listed in the New Drug Application.
The company noted that the inspection at the facility did not involve ABBV-951 or any AbbVie medicine. AbbVie stated that the CRL does not request that AbbVie conduct additional efficacy and safety trials related to the drug or device-related testing.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com